Michael Hedvat | Associate Director
Xencor, Inc.

Michael Hedvat, Associate Director, Xencor, Inc.

Michael Hedvat, Ph.D., is Associate Director of cell biology at Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Prior to joining Xencor in 2015, Dr. Hedvat was a research scientist in the translational oncology group at Kyowa Hakko Kirin. He received his B.S. at University of California, Santa Barbara and his Ph.D. in molecular and cell biology from City of Hope and completed postdoctoral training at the Sanford-Burnham Medical Research Institute.


Festival of Biologics Day 1 @ 17:30

Multispecific antibodies enabling targeted co-stimulation and cytokine mimetics to treat solid tumors

  • Xencor is developing bispecific antibodies targeting B7H3 x CD28 and PDL1 x PDL2 x CD28 to enhance the activity of neo-antigen reactive cells in the tumor microenvironment and to enhance activity of CD3 bispecific T cell engagers.
  • Xencor is engineering next generation cytokine mimetics enabling targeted delivery of cytokines to T cells by coupling them with immune checkpoint receptor antibodies.
  • Xencor is engineering next generation trispecific antibodies that can provide targeted costimulation or other signals to the tumor microenvironment
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers